Navigation Links
Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Date:9/5/2007

New "Oxygen Sandwich" Device is First to Mimic Natural Physical Environment

MIAMI, Sept. 5 /PRNewswire/ -- One of the major challenges to islet cell transplantation as the treatment of choice for type 1 diabetes is the shortage of donor tissue supply. Patients often need a re-infusion of islet cells after the initial treatment, and this means another donor pancreas is needed to provide the fragile islet cells for transplant. New findings by researchers at the Diabetes Research Institute (http://www.diabetesresearch.org) at the University of Miami could represent a big step forward in possibly alleviating the problem.

Up until now investigators have had only moderate success in differentiating either adult stem cells or embryonic stem cells to become insulin-producing beta cells. A large part of the problem has been inducing the proper culture environment in the laboratory. Researchers know that islets require a high amount of oxygen for optimal health, so UM researchers created a new cell culture device called the "oxygen sandwich" to provide the cells with a more natural oxygen environment than those used in traditional culture methods.

"Using mouse pancreatic stem cells, we were able to show that delivering oxygen in a physiological way enhanced enormously their differentiation into beta cells, with insulin levels exceeding 30-fold those observed in control conditions," said Juan Dominguez-Bendala, Ph.D., research assistant professor of surgery, director of the Stem Cell Development and Translational Research Laboratory at the Diabetes Research Institute, and senior author of the study which was published online in Stem Cells Express.

"It is as though these stem cells were just waiting for us to provide them with the conditions they needed to mature. We believe this is a major step toward the efficient generation of beta cells for clinical transplantation."

The new cell culture device, designed by Chris Fraker, senior research associate in the Tissue Engineering Laboratory at the Diabetes Research Institute, closely mimics the natural oxygen environment. The device "sandwiches" the stem cells with oxygen from two sources, one from the top with air diffusing through the culture medium and the second from the bottom with air diffusing through a silicon membrane mixed with perfluorocarbon, a very powerful oxygen reservoir.

"The use of high oxygen to promote differentiation of insulin-producing cells opens the way to many other applications with different sources of progenitor cells, beyond embryonic stem cells and beyond diabetes," said Camillo Ricordi, M.D., scientific director of the Diabetes Research Institute.

About the Diabetes Research Institute

The Diabetes Research Institute is a recognized world leader in cure- focused research. Since its inception in the early 1970s, the DRI has made significant contributions to the field of diabetes research, pioneering many of the techniques used in islet transplantation. From innovations in islet isolation and transplant procedures to advances in cell biology and immunology, the DRI is now harnessing the power of emerging technologies to develop new cell-based therapies to restore insulin production. For the millions of families already affected by diabetes who are looking to the world of science for answers, the Diabetes Research Institute is the best hope for a cure.


'/>"/>
SOURCE Diabetes Research Institute Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas S.A. ... cash tender offer (the "Tender Offer") to purchase ... aggregate principal amount of its 6.500% Senior Notes ... Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection with ... "Consent Solicitation") consents (the "Consents") of the holders ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , ... of pharmaceutical products, garnering increased attention from all stakeholders in the development of ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
Breaking Medicine News(10 mins):